Table 3. SARS-CoV-2 vaccination and flares in patients with inflammatory/autoimmune rheumatic and musculoskeletal diseases.
| IJDn=5207 | CTDn=1320 | Vasculitisn=686 | OIRMDn=123 | All patientsn=7336 | |
| Vaccine administered | |||||
| Pfizer | 3446 (66.2) | 973 (73.7) | 517 (75.4) | 93 (75.6) | 5029 (68.6) |
| Moderna | 508 (9.8) | 118 (8.9) | 63 (9.2) | 6 (4.9) | 695 (9.5) |
| AstraZeneca | 934 (17.9) | 158 (12) | 94 (13.7) | 14 (11.4) | 1200 (16.4) |
| Janssen | 154 (3) | 25 (1.9) | 4 (0.6) | 0 | 183 (2.5) |
| Sputnik V | 6 (0.1) | 1 (0.1) | 0 | 0 | 7 (0.1) |
| CoronaVac/Sinovac | 31 (0.6) | 22 (1.7) | 6 (0.9) | 10 (8.1) | 69 (0.9) |
| Other | 3 (0.1) | 0 | 1 (0.1) | 0 | 4 (0.1) |
| Number of doses administered | |||||
| One | 935 (18) | 229 (17.3) | 121 (17.6) | 15 (12.2) | 1300 (17.7) |
| Two | 4272 (82) | 1091 (82.7) | 565 (82.4) | 108 (87.8) | 6036 (82.3) |
| Flare following vaccination | |||||
| Yes | 206 (4) | 38 (2.9) | 22 (3.2) | 6 (4.9) | 272 (3.7) |
| No | 5001 (96) | 1282 (97.1) | 664 (96.8) | 117 (95.1) | 7064 (96.3) |
CTDconnective tissue diseaseIJDinflammatory joint diseaseOIRMDother inflammatory rheumatic and musculoskeletal disease